Lantheus Holdings, Inc. (NASDAQ:LNTH) CFO Robert J. Jr. Marshall Sells 10,000 Shares of Stock

Lantheus Holdings, Inc. (NASDAQ:LNTH) CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. This trade represents a 8.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Lantheus Stock Up 1.0 %

Lantheus stock opened at $103.28 on Thursday. Lantheus Holdings, Inc. has a 52-week low of $57.78 and a 52-week high of $126.89. The firm’s fifty day moving average is $92.54 and its 200 day moving average is $96.68. The company has a market cap of $7.07 billion, a price-to-earnings ratio of 17.18 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). The business had revenue of $391.11 million for the quarter, compared to analysts’ expectations of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lantheus

Institutional investors and hedge funds have recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC lifted its position in Lantheus by 16.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,184 shares of the medical equipment provider’s stock worth $374,000 after buying an additional 576 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Lantheus during the 4th quarter worth approximately $13,081,000. Mackenzie Financial Corp boosted its holdings in Lantheus by 4,907.1% during the 4th quarter. Mackenzie Financial Corp now owns 217,056 shares of the medical equipment provider’s stock valued at $19,418,000 after acquiring an additional 212,721 shares during the period. Peak Retirement Planning Inc. bought a new position in Lantheus in the 4th quarter valued at $917,000. Finally, Woodline Partners LP increased its stake in Lantheus by 2.7% in the fourth quarter. Woodline Partners LP now owns 88,018 shares of the medical equipment provider’s stock worth $7,874,000 after purchasing an additional 2,340 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Ratings Changes

LNTH has been the subject of several recent analyst reports. Truist Financial upped their price target on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. The Goldman Sachs Group initiated coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price for the company. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. Finally, StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and an average target price of $132.86.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.